 |
Prostatitis is associated with Prostate Cancer (ref. AACR); Prostatitis
was evident in more than 1100 consecutive patients with Prostate Cancer (ref: Dianon Labs) |
| |
|
 |
An EPS (expressed prostatic secretion) of >10 WBCs/HPF denotes prostate
inflammation/infection associated with Prostatitis (Stamey TG, Meares E etal.) |
| |
|
 |
Prostate health was re-established in virtually all patients who
remained on Peenuts at 2-3 capsules per day (n=102) |
| |
|
 |
All patients on PEENUTS improved the health of their prostate by
lowering the EPS, by an average of 69% |
| |
|
 |
Range of ages of patients who have benefited from PEENUTS: 19 years – 86
years |
| |
|
 |
Time to improvement of EPS varies based on severity of disease, duration
of disease and size of the prostate |
| |
|
 |
Men who take Peenuts as directed are expected to resolve Prostatitis
signs and symptoms over time including Urinary symptoms, PSA and EPS |
| |
|
 |
Most dramatic patient EPS improvement noted in clinical trials was TNTC
(too numerous to count) WBCs/HPF (high power field) decreasing to 0-3 WBCs/HPF in only 12 months |
| |
|
 |
PEENUTS is the only prostate nutritional product in the world to
demonstrate effectiveness versus Prostatitis based on the evaluation of EPS (Expressed Prostatic Secretion) (ref:
Review of United States Patents) |
| |
|
 |
PEENUTS was patented March 6, 2001 versus Prostatitis |
| |
| Patient EPS Data (Private Practice
Subset) |
| |
| INITIALS |
EPS (Mean) |
F/U EPS |
% CHANGE |
TIME TO SURVEILLANCE |
COMMENTS |
| D.L. |
310 |
210 |
32% |
12 mo. |
HGPIN |
| A.C. |
125 |
6 |
95% |
12 mo. |
Prostate Cancer (PC) |
| R.D. |
160 |
36 |
78% |
12 mo. |
PC |
| J.F. |
400 |
185 |
54% |
18 mo. |
PC |
| K.H. |
275 |
27 |
90% |
12 mo. |
PC |
| G.H. |
100 |
75 |
25% |
14 mo. |
PC |
| R.P. |
300 |
200 |
33% |
6 mo. |
PC |
| R.D. |
500 |
50 |
90% |
12 mo. |
PC |
| C.H. |
113 |
70 |
38% |
6 mo. |
|
| B.P. |
200 |
38 |
81% |
12 mo. |
|
| D.S. |
268 |
25 |
91% |
18 mo. |
|
| R.A. |
90 |
35 |
61% |
9 mo. |
|
| M.H. |
150 |
95 |
37% |
6 mo. |
|
| I.R. |
256 |
70 |
73% |
14 mo. |
|
| L.M. |
300 |
263 |
12% |
6 mo. |
|
| S.W. |
295 |
70 |
76% |
12 mo. |
|
| W.P. |
83 |
60 |
28% |
6 mo. |
|
| B.M. |
400 |
125 |
69% |
12 mo. |
|
| C.M. |
300 |
100 |
67% |
13 mo. |
|
| B.R. |
165 |
160 |
3% |
6 mo. |
|
| S.S. |
150 |
95 |
37% |
12 mo. |
|
| A.M. |
256 |
70 |
73% |
15 mo. |
|
| S.A. |
42 |
11 |
74% |
12 mo. |
|
| N.F. |
65 |
100 |
54%(+) |
6 mo. |
|
| S.G. |
160 |
26 |
84% |
11 mo. |
|
| R.G. |
400 |
38 |
91% |
14 mo. |
|
| F.H. |
20 |
7 |
65% |
48 mo. |
|
| S.H. |
50 |
8 |
84% |
8 mo. |
|
| B.H. |
450 |
110 |
76% |
10 mo. |
|
| M.H. |
300 |
65 |
78% |
9 mo. |
|
| B.I. |
450 |
70 |
84% |
11 mo. |
|
| J.K. |
210 |
135 |
36% |
8 mo. |
|
| M.K. |
190 |
48 |
75% |
8 mo. |
|
| E.L. |
105 |
15 |
86% |
18 mo. |
|
| T.L. |
325 |
155 |
52% |
48 mo. |
|
| B.M. |
20 |
12 |
40% |
9 mo. |
|
| K.M. |
48 |
35 |
27% |
15 mo. |
|
| D.G. |
325 |
12 |
96% |
36 mo. |
|
| J.M. |
105 |
85 |
19% |
36 mo. |
|
| E.M. |
290 |
30 |
90% |
10 mo. |
|
| W.M. |
300 |
35 |
88% |
25 mo. |
|
| S.K. |
210 |
10 |
95% |
12 mo. |
|
| W.M. |
350 |
140 |
60% |
24 mo. |
|
| W.M. |
140 |
45 |
68% |
18 mo. |
|
| J.N. |
275 |
100 |
64% |
5 mo. |
|
| A.D. |
80 |
25 |
69% |
4 mo. |
|
| D.A. |
70 |
16 |
77% |
4 mo. |
|
| C.B. |
80 |
13 |
84% |
4 mo. |
|
| B.C. |
235 |
154 |
35% |
4 mo. |
|
| C.F. |
170 |
35 |
79% |
4 mo. |
|
| F.C. |
340 |
65 |
81% |
4 mo. |
|
| F.W. |
256 |
113 |
56% |
12 mo. |
|
| J.B. |
85 |
15 |
82% |
12 mo. |
|
| S.A. |
325 |
190 |
42% |
12 mo. |
|
| S.A. |
190 |
60 |
68% |
12 mo. |
|
| J.C |
350 |
158 |
55% |
12 mo. |
|
| W.G. |
TN |
TC |
5 99% |
24 mo. |
|
| R.J. |
268 |
17 |
94% |
12 mo. |
|
| D.S. |
375 |
150 |
60% |
12 mo. |
|
| G.P. |
205 |
9 |
96% |
24 mo. |
|
| C.B. |
350 |
30 |
91% |
12 mo. |
|
| L.R. |
275 |
70 |
75% |
12 mo. |
|
| E.E. |
185 |
35 |
81% |
12 mo. |
|
| R.N. |
175 |
60 |
66% |
18 mo. |
|
| P.R. |
400 |
130 |
68% |
9 mo. |
|
| D.S. |
131 |
15 |
89% |
14 mo. |
|
| J.R. |
50 |
31 |
38% |
6 mo. |
|
| W.S. |
80 |
40 |
50% |
13 mo. |
|
| D.S. |
225 |
140 |
38% |
14 mo. |
|
| T.S. |
400 |
40 |
90% |
13 mo. |
|
| W.S. |
TNTC |
28 |
94% |
22 mo. |
|
| D.S. |
110 |
70 |
36% |
6 mo. |
|
| J.W. |
105 |
16 |
85% |
36 mo. |
PC |
| M.W. |
88 |
35 |
60% |
8 mo. |
|
| W.W. |
TNTC |
50 |
90% |
9 mo. |
PC |
| K.W. |
200 |
25 |
88% |
24 mo. |
|
| J.M. |
TNTC |
105 |
79% |
10 mo. |
PC |
| T.M. |
175 |
90 |
49% |
36 mo. |
|
| J.K. |
268 |
156 |
42% |
24 mo. |
|
| R.S. |
80 |
40 |
50% |
12 mo. |
|
| D.S. |
225 |
140 |
38% |
26 mo. |
|
| A.W. |
278 |
40 |
86% |
5 mo. |
|
| S.P. |
110 |
30 |
73% |
1 mo. |
|
| J.M. |
125 |
70 |
44% |
3 mo. |
|
| J.W. |
90 |
40 |
56% |
2 mo. |
|
| F.R. |
238 |
175 |
27% |
1 mo. |
|
| R.S. |
60 |
21 |
65% |
2.5 mo. |
|
| R.A. |
30 |
10 |
67% |
2 mo. |
|
| J.M. |
45 |
4 |
91% |
9.5 mo. |
|
| R.G. |
110 |
93 |
16% |
2 mo. |
|
| D.I. |
25 |
13 |
48% |
1.5 mo. |
|
| R.D. |
22 |
5 |
77% |
1.5 mo. |
|
| M.P. |
500 |
50 |
90% |
8 mo. |
|
| R.M. |
175 |
30 |
83% |
1.5 mo.
|
|
| R.K. |
500 |
130 |
74% |
6 mo.
|
|
| F.B.
|
48
|
13 |
73%
|
4 mo. |
|
| N.E.
|
140
|
55 |
61%
|
2 mo. |
|
| J.S. |
45 |
7 |
84%
|
6 mo. |
|
| J.F. |
110 |
25 |
77% |
12 mo. |
|
| P.H.
|
90 |
50 |
44%
|
6 mo. |
|
| J.Q. |
38 |
13 |
66% |
15 mo.
|
|
| R.V. |
130 |
35 |
73% |
9 mo.
|
|
| |
|
|
|
|
|
|